<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01591629</url>
  </required_header>
  <id_info>
    <org_study_id>1108008940</org_study_id>
    <nct_id>NCT01591629</nct_id>
  </id_info>
  <brief_title>The Effects of âˆ†-9-THC and Naloxone in Humans</brief_title>
  <official_title>Assessment of Cannabinoid-opiate Interactions in Humans With a Cannabis Use Disorder and Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to examine the effects of mu-opiate antagonism on the
      rewarding and reinforcing effects of delta-9-tetrahydrocannabinol (THC), the main
      psychoactive ingredient of cannabis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Behavioral Measures</measure>
    <time_frame>4 test days</time_frame>
    <description>Subjective effects and perceptual alterations will be assessed using the Positive and Negative Symptom Subscale (PANNS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analog scales</measure>
    <time_frame>4 test days</time_frame>
    <description>Will assess subjective effects, perceptual alterations, and cognitive effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician Administered Dissociative States Scales (CADSS)</measure>
    <time_frame>4 test days</time_frame>
    <description>Will measure subjective effects, perceptual alterations, and cognitive effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychotomimetic States Inventory (PSI)</measure>
    <time_frame>4 test days</time_frame>
    <description>Will assess subjective effects, perceptual alterations, and cognitive effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Marijuana Withdrawal Scale</measure>
    <time_frame>4 test days</time_frame>
    <description>Will assess subjective effects, perceptual alterations, and cognitive effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Opiate Withdrawal Scale</measure>
    <time_frame>4 test days</time_frame>
    <description>Will assess subjective effects, perceptual alterations, and cognitive effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Marijuana Craving Scale</measure>
    <time_frame>4 test days</time_frame>
    <description>Will assess subjective effects, perceptual alterations, and cognitive effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuro cognitive battery</measure>
    <time_frame>4 test days</time_frame>
    <description>Will assess cognitive effects.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo and Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Naloxone and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Active Delta-9-THC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Naloxone and Active Delta-9-THC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone</intervention_name>
    <description>Active Naloxone 18 mcg/kg intravenously over 60 minutes, 2mg IV push, 1mg IV push</description>
    <arm_group_label>Active Naloxone and Placebo</arm_group_label>
    <arm_group_label>Active Naloxone and Active Delta-9-THC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delta-9-THC</intervention_name>
    <description>Active Delta-9-THC (0.025mg/Kg) given intravenously over 20 minutes.</description>
    <arm_group_label>Placebo and Active Delta-9-THC</arm_group_label>
    <arm_group_label>Active Naloxone and Active Delta-9-THC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo and Placebo</arm_group_label>
    <arm_group_label>Active Naloxone and Placebo</arm_group_label>
    <arm_group_label>Placebo and Active Delta-9-THC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one exposure to Cannabis

        Exclusion Criteria:

          -  Cannabis Naive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2012</study_first_submitted>
  <study_first_submitted_qc>May 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2012</study_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Deepak C. D'Souza</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Cannabis</keyword>
  <keyword>Marijuana</keyword>
  <keyword>Naloxone</keyword>
  <keyword>THC</keyword>
  <keyword>Psychotic Disorders</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxone</mesh_term>
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

